Protein binding in a congeneric series of antibacterial quinolone derivatives

International Journal of Pharmaceutics

Volumn 169, Issue 2, 1998, Pages 229-238

  Zlotos, Gabriele ^a   Bücker, Annegret ^a   Jürgens, Jens ^a   Holzgrabe, Ulrike ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

N1 phenyl substituted quinolones; Plasma protein binding; QSAR

Indexed keywords

CIPROFLOXACIN; DIFLOXACIN; ENROFLOXACIN; GYRASE INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEMAFLOXACIN;

ARTICLE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; LIPOPHILICITY; PARTITION COEFFICIENT; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 0032528367     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(98)00126-4     Document Type: Article

References (15)

1. Derendorf, H., Garrett, E.R., 1987. Pharmakokinetik, 1st ed. Wiss. Verlagsges., Stuttgart, 102 pp.
2. Fichtl B., Nieciecki A., Walter K. Tissue binding versus plasma binding of drugs: General principles and pharmacokinetic consequences. Adv. Drug Res. 20:1991;118-166.
3. Hersey A., Hyde R.M., Livingstone D.J., Rahr E. A quantitative structure-activity relationship approach to the minimization of albumin binding. J. Pharm. Sci. 80:1991;333-337.
4. Jürgens, J., 1994. Thesis, Bonn, Germany.
5. Jürgens J., Schedletsky H., Heisig P., Seydel J.K., Wiedemann B., Holzgrabe U. Synthesis and biological activity of new N1-aryl substituted quinolone antibacterials. Arch. Pharm. Pharm. Med. Chem. 329:1996;179-190.
6. Kubinyi, H., 1993. Hansch Analysis and Related Approaches in QSAR. VCH, Weinheim.
7. Merino V., Freixas J., del Val Bermejo M., Garrigues T.M., Moreno J., Pla-Delfina J.M. Biophysical models as an approach to study passive adsorption in drug development: 6-fluoroquinolones. J. Pharm. Sci. 84:1995;777-782.
8. Montero M.T., Freixas J., Hernandez-Borrell J. Expression of the partition coefficients of a homologous series of 6-fluoroquinolones. Int. J. Pharm. 149:1997;161-170.
9. Oberdisse, E., 1997. In: Oberdisse, E., Hackenthal, E., Kuschinsky, K. (Eds.), Pharmakologie und Toxikologie, 1st ed. Springer Verlag, Heidelberg, p. 15.
10. Olson R.E., Christ D.D. Plasma protein binding of drugs. Annu. Rep. Med. Chem. 31:1996;327-336.
11. Proost J.H., Wierda J.M.K.H., Meijer D.K.F. An extended pharmacokinetic/pharmacodynamic model describing quantitatively the influence of plasma protein binding, tissue binding and receptor binding on the potency and time course of action of drugs. J. Pharmacokin. Biopharm. 24:1996;45-77.
12. Ross D.L., Riley C.M. Physicochemical properties of the fluoroquinolone antimicrobials. II acid ionization constants and their relationship to structure. Int. J. Pharm. 83:1992;267-272.
13. Sörgel F., Kinzig M. Pharmacokinetics of gyrase inhibitors, Part 1: Basic chemistry and gastrointestinal disposition. Am. J. Med. 94(3A):1993;44-55.
14. Takacs-Novak K., Noszal B., Hermecz I., Kereszturi G., Podanyi B., Szasz G. Protonation equilibria of quinolone antibacterials. J. Pharm. Sci. 79:1990;1023-1028.
15. Zlotos G., Bücker A., Kinzig-Schippers M., Sörgel F., Holzgrabe U. Plasma protein binding of gyrase inhibitors. J. Pharm. Sci. 87:1998;215-220.